NETRF Welcomes John Kanki, PhD, as New Research Director

John Kanki, PhD, has joined Neuroendocrine Tumor Research Foundation (NETRF) as Director of Research. In this position, Dr. Kanki will oversee the strategic, scientific, and operational goals of the NETRF research programs.

“John brings both scientific and granting expertise to the Foundation that will help us continue to expand and innovate,” said Elyse Gellerman, NETRF Chief Executive Officer.

Before joining NETRF, Dr. Kanki served as Managing Director at The Medical Foundation for eight years where he developed ten new grant programs, conducted over twenty life sciences consulting projects, and supervised the management of sixteen concurrent award programs across a broad range of scientific disciplines and program missions.

“At NETRF, I will be working to widen and deepen the Foundation’s research portfolio across the spectrum of basic and translational research to move the field forward towards improved NET diagnostic and treatment options, said John Kanki, PhD, NETRF Director of Research.

Dr. Kanki is an accomplished research scientist with an extensive publication record. He received a PhD in Biology and conducted postdoctoral research in neurobiology, developmental biology, and pancreas organogenesis/diabetes. As a Senior Research Scientist at the Dana‐Farber Cancer Institute for twelve years, he received the Partners in Excellence Award and supervised research in myelodysplastic syndromes, leukemia, and neuroblastoma.

Dr. Kanki serves on the Board of Directors for the Health Research Alliance, a group of over 80 private funders working together to optimize investment in health research and training, share best practices, and collectively provide over $1.5 billion annually in biomedical research.